ä»æ¥æãã¤ãããã¨ãã¤ãã¤ãã¨ã èªåã¯PCã¯ããããã§ãããPCã¹ãã«ã§ãããããã£ã¦ããã®ãå¤æã¯é£ãããã©ã ã¾ãè·å ´ã®ãããããã°ãããããã£ã¦ãPCã®ãã¨ã¯ããã¤ã«èãã¦ããããã£ã¦æ¥ãæãã®ã¬ãã«ã å½¼ãã¯ãå ¨ããã½ã³ã³ã£ã¦ã®ã¯ããããããªãããªããã¨ããã®ãå£çã§ã ã¾ãèªåã§ç¥èãã¹ãã«ã身ã«ã¤ãããã¨ããæãã§ã¯ãªãã ã§ããã®å ´åãè·å ´ã§ã¯å½¹ã«ç«ã¤äººéã¨ããè©ä¾¡ãããããã®ã§ãé ¼ãããã®ã¯æªãæ°ã¯ããªãã ãã¡ã®è·å ´ã®çµçãã£ã¦ãããã°ãããã PCã¯è¾ããã¦é常æ¥åã§æ £ãã¦ããåã ãã¯ããªããããã¤ã¬ã®ã¥ã©ã¼ãªå¦çã«ã¤ãã¦ã¯å ¨ããæä¸ãã¨ãã£ãã¬ãã«ã ãã®ãã°ããããPCã®ãã¨ã¯èªåã«ããèãã¦ããããèªåãæ®éã«ããããã¨æãã¦ãããããã¦ãã ã§ããã®ãã°ãããé»åæã¤ã®ããããéãã£ãã ãã£ãã¼ãªãã¨å¸¸ã æã£ã¦ãã®ã ããããæ¥é»åæ¤å®ãªããã®ãããã®ãèãã¤
ä¸çãè¦æ¸¡ãã¦ãå¸ãªãããè±ãã§å®å ¨ãªæ®ãããã§ããå½ï¼ï¼ãæµ·å¤ã®æ¥æ¬ã«å¯¾ããããããè©å¤ãè³ã«ãããã¨ã¯å¤ããããããçæ´»å®æã¯ãã®è©ä¾¡ãè£åããã®ã§ã¯ãªãã ãããã é£ã¹ç©ã«è¾²è¬ãæ··ãã£ã¦ãããå¹´éå¶åº¦ã¯å´©å£å¯¸åã§èå¾ãå¿é ã ãåãããã¦ãä»äºããªãâ¦â¦ããã¾ãã¾ãªãªã¹ã¯ã社ä¼ã«åºãã£ã¦ããããã¨ãâå®å ¨âã§ãã¾ã£ããâå®å¿âã§ããªãã¨ããæããæ£ç´ãªã¨ããã§ã¯ãªããã ãªã¹ã¯ã«å¯¾ãã人ã®å¿ççå´é¢ã解æããã®ãããªã¹ã¯èªç¥ç 究ãã ããã®åéãå°æ»ããä¸è°·å ä¸ä¹ããã¯ãããªãå®å ¨ãå®å¿ã«ã¤ãªãããªãããããªã¹ã¯èªç¥ã®ç«å ´ããç 究ãã¦ãããå®å ¨ã®è¿½æ±ããªãå®å¿ã®ç¢ºä¿ã«ãªããªãã®ããåç·¨ã§ã¯å®å ¨ã¨å®å¿ã®éãã«ã¤ãã¦èããã ï¼ï¼ããæ°å¹´ãå½æ°ã®ä¿¡é ¼ã失å¢ããã社ä¿åºã®å¹´éåé¡ããä¸å½è£½ã®æ¯å ¥ãé¤åäºä»¶ãçèå½è£ äºä»¶ãªã©ã®ããã«ãæ®ãããä¸å®ã«ãããåºæ¥äºãå¤æ°çºçãã¾ãããããããäºä»¶ã¸ã®
梶浦ç±è¨ã®å人ããã¸ã§ã¯ããFï½ï½ï½ï½ï½ï½ï¼ªï½ï½ï½ï½ï½ï½ï½ãã®ã©ã¤ãããã¼ã«é¢¨ã®è¡£è£ ãã¾ã¨ã£ã女æ§ãã¼ã«ã«ï¼äººã®æ声ãå¹»æ³çãªä¸çã¸ã¨ãããªã梶浦ç±è¨ ãã¢ãã¡ä½åã§ä½¿ããã楽æ²ã§ããã¢ãã¡ã½ã³ã°ãç¥ãã¦ãã¢ãã½ã³ããç±ãããã£ã©ã¯ã¿ã¼ãã¤ã¡ã¼ã¸ãã¦ã¤ããããããã£ã©ã½ã³ããããããã£ã¼ããã«ããããã¢ãã½ã³ã®ã¯ãªã¨ã¼ã¿ã¼ãææã®æ´»èºãç®è¦ã¾ãããé³æ¥½ã®ã¸ã£ã³ã«ã®ä¸ã¤ã¨ãã¦åå¨æãå¢ãã¦ããã ãï¼æï¼ï¼æ¥ä»ãªãªã³ã³ã®é±éã©ã³ãã³ã°ã§ï¼ä½ãç²å¾ããã·ã³ã°ã«ï¼£ï¼¤ãGOï¼ãGOï¼ãï¼ï¼¡ï¼®ï¼©ï¼¡ï¼£ãã¨ï¼ä½ã®ãLï½ï½ï½ï½ ï½ï¼ï¼ããã¢ãã¡ãããããï¼ï¼ãã®ä¸»äººå ¬ãã¡ãçµããã³ããæ¾èª²å¾ãã£ã¼ã¿ã¤ã ãå義ã§å£°åªï¼äººãæã£ãæ²ã ãã¢ãã¡ãã£ã©ã¯ã¿ã¼å義ã¨ãã¦ã¯ãªãªã³ã³ã®ã·ã³ã°ã«ã©ã³ãã³ã°å²ä¸åã®ï¼ä½ãï¼æï¼æ¥çºå£²ã®æ°æ²ï¼æ²ãï¼ï¼æ¥ä»ã§ãï¼³ï¼ï¼¡ï¼°ã«æ¬¡ãï¼ä½ã¨ï¼ä½ã«ã©ã³ã¯ã¤ã³ããã â ä¸»äººå ¬ãæãããã£ã©ã½ã³
ä»ã«ã³ï¼Caenï¼ã§æ®å½±ããããä»å»è¬åã¡ã¼ã«ã¼HRA Pharmaã®ç·æ¥çµå£é¿å¦è¬ï¼ã¢ã¼ãã³ã°ã¢ãã¿ã¼ãã«ï¼ãEllaOneãï¼2009å¹´10æ13æ¥æ®å½±ï¼ã(c)AFP/MYCHELE DANIAU ã8æ16æ¥ AFPãç±³é£åå»è¬åå±ï¼Food and Drug AdministrationãFDAï¼ã¯13æ¥ãç¡é²åãªæ§äº¤æ¸ããã¦ã5æ¥ä»¥å ã«æç¨ããã°é¿å¦ãå¯è½ã«ãªãç·æ¥çµå£é¿å¦è¬ï¼ã¢ã¼ãã³ã°ã¢ãã¿ã¼ãã«ï¼ãEllaãã®è²©å£²ãèªå¯ããã ãEllaãã¯ãä»å»è¬åã¡ã¼ã«ã¼HRA Pharma製ãFDAã¯2度ã®ç¬¬3ç¸æ²»é¨ã§ãå¹è½ããã³å®å ¨æ§ã«ã¤ãã¦èª¬å¾åã®ãããã¼ã¿ãå¾ãããããé¿å¦ã«å¤±æããã¨ããé¿å¦å ·ãç¨ããªãæ§è¡çºã®å¾ã120æé以å ã«çµå£æåãããã¨ã§ãé¿å¦ã«æåãããã¨ãã¦ã販売ãèªå¯ãããã¨ã声æã§æããã«ããã ãã ãFDAã¯ãé¿å¦è¬ã¨ãã¦ã®å¸¸ç¨ä½¿ç¨ã¯é¿ããã¹ãã ã¨ãä»ãå
ããã©ãæè¡ãªã©ãåå ã§ç®èãçãä¸ããã±ãã¤ãã®çºçã«ããããéºä¼åããæ±äº¬å¤§å»ç§å¦ç 究æã¨çåå¦ç 究æã®ç 究ãã¼ã ãçªãæ¢ããï¼ï¼æ¥ãç±³ç§å¦èªãã¤ãã£ã¼ã¸ã§ããã£ã¯ã¹ï¼é»åçï¼ã«çºè¡¨ãããçç¶ãæããæ°è¬ã®éçºã«å½¹ç«ã¤ææã¨ããã ã±ãã¤ãã¯ãè¸é¨ãè©ãªã©ã«çºçãããããçã¿ãããã¿ãä¼´ããè¥ã女æ§ã§çç¶ãå¼·ãåºãããå¾åãããããã¢ã¹ã®ç©´ã«ã§ããå ´åããããç¾å®¹ã®è¦³ç¹ããã大ããªèª²é¡ã«ãªã£ã¦ãããåé¤ãè»ããã«ããæ²»çãä¸è¬ã ããåçºãããã¨ãå¤ããè¦ããæ£è ãå°ãªããªãã ç 究ãã¼ã ã¯ãæ¥æ¬äººã®ã±ãã¤ãæ£è ï¼ï¼ï¼äººã¨ãå¥åº·ãªäººï¼ï¼ï¼ï¼äººã§ã²ãã ï¼å ¨éºä¼æ å ±ï¼ãæ¯è¼ããã ãã®çµæã両è ã®éã§ãï¼çªæè²ä½ã¨ï¼ï¼çªæè²ä½ã®åï¼ã«æãï¼çªæè²ä½ã®ï¼ã«æã®è¨ï¼ã«æã§ãéºä¼æ å ±ãæ§æããåå¦ç©è³ªãå¡©åºãã®ä¸¦ã³æ¹ã«éããããã®ãçºè¦ãããï¼ã«æã®ãã¡ãç´°èå士ããã£ã¤ãã®ãå¶å¾¡ãããæ§ãã«ã¢ã³
ç°ä¸å®ï¼28æ³ããããã·ãã£å¨ä½ï¼ã¤ã³ãã«ã¨ã³ãµã¼ @k4403 çºå»è ã«ã¯éçããã£ã¦ï¼å¸¸ã«ããããä¸çã«æ¥ãã¦ãªãããããªãã£ã¦ï¼ãªã¬ãä»åã§ããæã£ããï¼ããååãããï¼åã åãï¼ watching: å»è ã®å½ããå¤ãã§ãããªã«éãã¨ãã話 - http://anond.hatelabo.jp/20100816114659 2010-08-16 14:03:19 ç°ä¸å®ï¼28æ³ããããã·ãã£å¨ä½ï¼ã¤ã³ãã«ã¨ã³ãµã¼ @k4403 çæ£è ãªãã¦ã¿ãªãçºå»è ãå³ãè¾¼ãã§ã¦ã風éªã£ã½ããã§ããã£ã¦ä¸»å¼µããæ£è ãæ¥ãã風éªè¬å¦æ¹ããã ãjkï¼ãããªãçãçããªãã ãï¼å¤§å¦ç é¢ã¨ãã¯æ¥å¸¸è¶é£¯äºã ããè¦ããªã解ããã ãããªãã¨æãï¼ãªã¬ã ã£ã¦æ¤æ»åããUCçããã¦ãä½ã ãï¼ä½ãè ¸å ã«ã©ããªç´°èãããã調ã¹ã¦ãã¦ã ãï¼ 2010-08-16 14:05:46
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
å¼·åãªå¤å¤èæ§èãæ¡æ£ï¼ã¤ã³ãã»ããã¹ã¿ã³ããâåã®æ»è ãç£è¦è¨´ãã»å½éãã¼ã 8æ17æ¥0æ2åé ä¿¡Â æäºéä¿¡ æçç©è³ªãã»ã¨ãã©å¹ããªããªãéºä¼åãæã¤å¤å¤èæ§èãã¤ã³ããããã¹ã¿ã³ã§åºããã両å½ã«æ è¡ãã¦ææããä¾ãå¢ãã¦ããã¨ãã¤ã³ãã»ããã©ã¹å¤§ãè±å¥åº·ä¿è·åºï¼HPAï¼ãªã©ã®å½éç 究ãã¼ã ã16æ¥ã¾ã§ã«è±å»å¦èªã©ã³ã»ããé»åçã«çºè¡¨ããã AFPéä¿¡ã«ããã¨ãããã¹ã¿ã³ã§äº¤éäºæ ã«éããå ¥é¢ããéã«ãã®èæ§èã«ææãããã«ã®ã¼äººç·æ§ã帰å½å¾ã®6æã«æ»äº¡ãæåã®æ»è ã¨å ±ãããããã¤ã³ããªã©ã§æ²»çãåããéã«ææãã人ã¯è±å½ããªã¼ã¹ãã©ãªã¢ã§ãè¦ã¤ãã£ãã ãã®éºä¼åã¯ããã¥ã¼ããªã¼ã»ã¡ã¿ããã¼ã¿ã©ã¯ã¿ãã¼ã¼1ï¼NDMâ1ï¼ãã¨å¼ã°ããé µç´ ãä½ãåãããããå¤§è ¸èãèºçæ¡¿ï¼ããï¼èãªã©ãã¾ãã¾ãªç´°èã«åºãã£ã¦ãããç 究ãã¼ã ã¯ãNDMâ1éºä¼åãæã¤ç´°èãä¸çåå°ã«æ¡æ£ããå¯è½æ§ã
ããããæ¸ããããã¨ããããããå¦çã®åè«æå°ã¯çå®ã«é²ããªããã°ãªããªãã ããã¾ã§ä¸åº¦ãæç« ãèªåã«è¦ãã¦ããªãã£ãå¦çï¼è«æã®ç« ç«ã¦ããä½åº¦è¨ã£ã¦ãåºããªãã£ãï¼ã«ãã¤ã注æãããã¨ãããã¤ãã«2000åãã¾ãã®å稿ãéããã¦ãããæ·»ä»ãã¡ã¤ã«ã§ã¯ãªããã¡ã¼ã«æ¬æã¨ãã¦ã ééããªãèªåã®è¨èã§æ¸ããã¦ãããã³ããã¯ããããä¸ã¶æããªãã ããããã ãããã®ããã«æåããæå¾ã¾ã§æ¥æ¬èªè¡¨ç¾ãå®å ¨ã«ç ´ç¶»ãã¦ããã æ¬å½ã«å¤§å¦4åçãæ¸ããæç« ãªã®ã ããã・・・ã大ããã§ã¯ãªããå½èªãè¦æãªå°å¦çãæ¸ããã¨è¨ããã¦ããã¶ãå¤ãã®äººãä¿¡ãããããã¡ãã£ã¨æ¼¢åãå¤ãããªããããã§ãä¸æãæ¸ãå§ããã¨ãã®ä¸»èªããæ¸ãçµããé ã«ã¯å¿ãã¦ããã®ã ããããå¦ç«¥ä¿è²æã«æ¯æ´ã§éã£ã¦ããã¨ãã«ä½å¦å¹´ã®åã©ãããããã£ãæç´ã¨äºè§ã®ã¬ãã«ã§ãããæ¬å½ã«èªå¼µãã¦ããããã§ã¯ãªãã®ã ãã¡ãã£ã¨ä¿¡ããããã ãã¡
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}